ADMA FY 2019 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+72.8% YoY

Gross Profit

-$10M-34.6% margin

Operating Income

-$41M-141.1% margin

Net Income

-$48M-164.5% margin

EPS (Diluted)

$-1.05

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$80M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$127M

Total Liabilities

$101M

Stockholders' Equity

$26M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$17M	+72.8%
Gross Profit	-$10M	-$25M	+59.7%
Operating Income	-$41M	-$60M	+31.3%
Net Income	-$48M	-$66M	+26.6%